Kunihiro Yamaoka

List of Publications by Year
in descending order

51	2,583	304743	214800
papers	citations	22 h-index	47 g-index

53	53	53	3912
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Janus kinases (Jaks). Genome Biology, 2004, 5, 253.	8.8	508
2	Janus kinase inhibitors in autoimmune diseases. Annals of the Rheumatic Diseases, 2013, 72, ii111-ii115.	0.9	350
3	The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferonâ€Î³ and interleukinâ€17 production by human CD4+ T cells. Arthritis and Rheumatism, 2012, 64, 1790-1798.	6.7	196
4	Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy. Arthritis and Rheumatology, 2017, 69, 1960-1968.	5.6	182
5	Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. Annals of the Rheumatic Diseases, 2015, 74, 389-395.	0.9	149
6	The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Annals of the Rheumatic Diseases, 2014, 73, 2192-2198.	0.9	136
7	Janus kinase inhibitors for rheumatoid arthritis. Current Opinion in Chemical Biology, 2016, 32, 29-33.	6.1	112
8	Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology, 2019, 58, i4-i16.	1.9	111
9	Efficacy of combination therapy of anti-TNF-Î± antibody infliximab and methotrexate in refractory entero-BehÃ§etâ€™s disease. Modern Rheumatology, 2011, 21, 184-191.	1.8	69
10	The combination of polymorphisms within interferon-Î³ receptor 1 and receptor 2 associated with the risk of systemic lupus erythematosus. FEBS Letters, 1999, 453, 187-190.	2.8	56
11	Jak3 negatively regulates dendritic-cell cytokine production and survival. Blood, 2005, 106, 3227-3233.	1.4	55
12	Low complements and high titre of anti-Sm antibody as predictors of histopathologically proven silent lupus nephritis without abnormal urinalysis in patients with systemic lupus erythematosus. Rheumatology, 2015, 54, 405-412.	1.9	55
13	JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Modern Rheumatology, 2013, 23, 415-424.	1.8	53
14	IL-6-accelerated calcification by induction of ROR2 in human adipose tissue-derived mesenchymal stem cells is STAT3 dependent. Rheumatology, 2014, 53, 1282-1290.	1.9	52
15	Spontaneous Differentiation of Human Mesenchymal Stem Cells on Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold. PLoS ONE, 2016, 11, e0153231.	2.5	46
16	Dopamine D2-like receptor signaling suppresses human osteoclastogenesis. Bone, 2013, 56, 1-8.	2.9	45
17	Efficacy and safety of upadacitinib in Japanese patients with rheumatoid arthritis (SELECT-SUNRISE): a placebo-controlled phase IIb/III study. Rheumatology, 2020, 59, 3303-3313.	1.9	41
18	Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology, 2014, 53, 914-918.	1.9	40

#	Article	IF	Citations
19	Tofacitinib, a JAK inhibitor, inhibits human B cell activation in vitro. Annals of the Rheumatic Diseases, 2014, 73, 2213-2215.	0.9	38
20	Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster. Drug Safety, 2016, 39, 823-840.	3.2	28
21	Incidence and risk factors for herpes zoster in patients with rheumatoid arthritis receiving upadacitinib: a pooled analysis of six phase III clinical trials. Annals of the Rheumatic Diseases, 2022, 81, 206-213.	0.9	25
22	Acquiring Chondrocyte Phenotype from Human Mesenchymal Stem Cells under Inflammatory Conditions. International Journal of Molecular Sciences, 2014, 15, 21270-21285.	4.1	22
23	Local Delivery of Mesenchymal Stem Cells with Poly-Lactic-Co-Glycolic Acid Nano-Fiber Scaffold Suppress Arthritis in Rats. PLoS ONE, 2014, 9, e114621.	2.5	21
24	Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Review of Clinical Immunology, 2019, 15, 577-588.	3.0	21
25	Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study. Rheumatology, 2017, 56, 1293-1301.	1.9	19
26	Human dendritic cell-derived osteoclasts with high bone resorption capacity and T cell stimulation ability. Bone, 2021, 142, 115616.	2.9	19
27	Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib. Expert Opinion on Pharmacotherapy, 2014, 15, 103-113.	1.8	17
28	Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Modern Rheumatology, 2013, 23, 1151-1157.	1.8	16
29	The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan. Drug Safety, 2021, 44, 711-722.	3.2	15
30	Association of the multi-biomarker disease activity score with joint destruction in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha inhibitor treatment in clinical practice. Modern Rheumatology, 2016, 26, 850-856.	1.8	14
31	Jak inhibitor ; possibility and mechanism as a new disease modifying anti-rheumatic drug. Japanese Journal of Clinical Immunology, 2009, 32, 85-91.	0.0	11
32	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. Modern Rheumatology, 2007, 17, 144-147.	1.8	10
33	A case of life-threatening refractory polychondritis successfully treated with combined intensive immunosuppressive therapy with methotrexate. Modern Rheumatology, 2007, 17, 144-147.	1.8	9
34	Detection of polymorphisms within the human IL10 receptor cDNA gene sequence by RT-PCR RFLP. Immunogenetics, 1997, 46, 439-441.	2.4	8
35	Jak and Syk: Emerging their relevance to the treatment of inflammatory diseases. Inflammation and Regeneration, 2011, 31, 237-244.	3.7	6
36	Rituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan. Modern Rheumatology, 2023, 33, 145-153.	1.8	6

#	Article	IF	Citations
37	Skeletal unloading reduces cluster of differentiation (CD) 38 expression in the bone marrow and osteoblasts of mice. Journal of Orthopaedic Science, 2020, 25, 331-337.	1.1	5
38	Thymus variants on imaging in patients with rheumatoid arthritisâ€”Clinical and immunological significance. Rheumatology, 2021, 60, 5595-5600.	1.9	2
39	Integrated safety analysis of filgotinib treatment for rheumatoid arthritis in patients from Japan over a median of 1.5â€‰years. Modern Rheumatology, 2023, 33, 64-72.	1.8	2
40	Clinical Images: Takayasu arteritis diagnosed by positron emission tomography. Arthritis and Rheumatism, 2007, 56, 2466-2466.	6.7	1
41	JAK inhibitor: tofacitinib, a new disease modifying anti-rheumatic drug. Inflammation and Regeneration, 2011, 31, 349-353.	3.7	1
42	The possible mode of action of Tofacitinib, a JAK inhibitor. Inflammation and Regeneration, 2014, 34, 129-133.	3.7	1
43	Mesenchymal stem cells: A new treatment tool for rheumatoid arthritis. Inflammation and Regeneration, 2012, 32, 188-192.	3.7	1
44	Regulatory role of mesenchymal stem cells in osteoclast differentiation. Inflammation and Regeneration, 2013, 33, 217-222.	3.7	1
45	è‡ªå·±å…ç–«ç–¾æ£æ²»ç™‚ã®ç™ºå±•ã•è²¢çŒ®. Drug Delivery System, 2020, 35, 376-383.	0.0	1
46	Safety of jakinibs: lessons from ORAL Surveillance. Rheumatology, 2022, 61, 4223-4225.	1.9	1
47	A Case of Rheumatoid Arthritis With Bilateral Shoulder Bursitis Accompanied by Gas Image. Modern Rheumatology Case Reports, 2022, , .	0.7	1
48	Overlap syndrome of polymyositis and progressive systemic sclerosis associated with interferon therapy for chronic hepatitis C. Japanese Journal of Rheumatology, 1999, 9, 259-265.	0.0	0
49	Overlap syndrome of polymyositis and progressive systemic sclerosis associated with interferon therapy for chronic hepatitis C. Japanese Journal of Rheumatology, 1999, 9, 259-265.	0.0	0
50	Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6Âmonths of abatacept treatment in routine clinical practice. The ALTAIR study. Modern Rheumatology, 2013, , 1.	1.8	0
51	Role of JAKs in myeloid cells and autoimmune diseases. Inflammation and Regeneration, 2013, 33, 131-135.	3.7	0